

B2  
Cont

4. (Twice Amended) The method of claim 1, wherein the arthrosis is rheumatoid arthritis.

5. (Twice Amended) The method of claim 1, wherein the arthrosis is osteoarthritis.

6. (Twice Amended) The method of claim 1, wherein the substance is a protein.

B3

7. (Amended) The method of claim 6, wherein the protein is selected from the group consisting of:

- a) an antibody that binds to AILIM or a portion thereof;
- b) a polypeptide comprising all or a portion of an extracellular region of AILIM;
- c) a fusion polypeptide comprising all or a portion of an extracellular region of AILIM and all or a portion of a constant region of an immunoglobulin heavy chain; and
- d) a polypeptide that binds to AILIM.

B4

8. (Twice Amended) The method of claim 1, wherein the substance is a non-protein substance.

9. (Amended) The method of claim 8, wherein the non-protein substance is DNA, RNA, or a chemically synthesized compound.

B5

10. (Amended) A method of preventing or treating inflammation in a subject, the method comprising administering the subject a composition comprising (a) a substance that modulates signal transduction mediated by AILIM, and (b) a pharmaceutically acceptable carrier, wherein the composition comprises an amount of the substance effective to prevent or treat inflammation in the subject.

11. (Amended) The method of claim 10, wherein the substance inhibits proliferation of AILIM-expressing cells or inhibits production of a cytokine by AILIM-expressing cells.

B5  
cont

12. (Amended) The method of claim 11, wherein the cytokine is interferon  $\gamma$  or interleukin 4.

---

B6

13. (Twice Amended) The method of claim 10, wherein the subject has hepatitis.

---

14. (Twice Amended) The method of claim 10, wherein the substance is a protein.

---

15. (Amended) The method of claim 14, wherein the protein is selected from the group consisting of:

- B7
- a) an antibody that binds to AILIM or a portion thereof;
  - b) a polypeptide comprising all or a portion of an extracellular region of AILIM;
  - c) a fusion polypeptide comprising all or a portion of an extracellular region of AILIM and all or a portion of a constant region of an immunoglobulin heavy chain; and
  - d) a polypeptide that binds to AILIM.
- 

B8

16. (Twice Amended) The method of claim 10, wherein the substance is a non-protein substance.

---

17. (Amended) The method of claim 16, wherein the non-protein substance is DNA, RNA, or a chemically synthesized compound.

---

B9

18. (Amended) A method of preventing or treating graft versus host reaction or immune rejection accompanying graft versus host reaction or transplantation of a tissue or organ in a subject, the method comprising administering to the subject a composition comprising (a) a substance that modulates signal transduction mediated by AILIM, and (b) a pharmaceutically acceptable carrier, wherein the composition comprises an amount of the substance effective to prevent or treat graft versus host reaction or immune rejection accompanying graft versus host reaction or transplantation of a tissue or organ in the subject.

B9  
Cont 19. (Amended) The method of claim 18, wherein the substance inhibits proliferation of AILIM-expressing cells or inhibits production of a cytokine by AILIM-expressing cells.

20. (Amended) The method of claim 19, wherein the cytokine is interferon  $\gamma$  or interleukin 4.

B10 21. (Twice Amended) The method of claim 18, wherein the substance is a protein.

22. (Amended) The method of claim 21, wherein the protein is selected from the group consisting of:

- B11
- a) an antibody that binds to AILIM or a portion thereof;
  - b) a polypeptide comprising all or a portion of an extracellular region of AILIM;
  - c) a fusion polypeptide comprising all or a portion of an extracellular region of AILIM and all or a portion of a constant region of an immunoglobulin heavy chain; and
  - d) a polypeptide that binds to AILIM.

B12 23. (Twice Amended) The method of claim 18, wherein the substance is a non-protein substance.

24. (Amended) The method of claim 23, wherein the non-protein substance is DNA, RNA, or a chemically synthesized compound.

B13 25. (Amended) A method of preventing or treating an immune response triggered by a foreign antigen or an autoantigen in a subject, the method comprising administering to the subject a composition comprising (a) a substance that modulates signal transduction mediated by AILIM, and (b) a pharmaceutically acceptable carrier, wherein the composition comprises an amount of the substance effective to prevent or treat an immune response triggered by a foreign antigen or an autoantigen in the subject.

B13  
Cont

26. (Amended) The method of claim 25, wherein the immune response comprises production of an antibody against the foreign antigen or the autoantigen, cell proliferation, or production of a cytokine.

B14

27. (Twice Amended) The method of claim 25, wherein the substance inhibits proliferation of AILIM-expressing cells or inhibits production of a cytokine by AILIM-expressing cells.

B15

28. (Amended) The method of claim 27, wherein the cytokine is interferon  $\gamma$  or interleukin 4.

B16

29. (Twice Amended) The method of claim 25, wherein the substance is a protein.

30. (Amended) The method of claim 29, wherein the protein is selected from the group consisting of:

- B17
- a) an antibody that binds to AILIM or a portion thereof;
  - b) a polypeptide comprising all or a portion of an extracellular region of AILIM;
  - c) a fusion polypeptide comprising all or a portion of an extracellular region of AILIM and all or a portion of a constant region of an immunoglobulin heavy chain; and
  - d) a polypeptide that binds to AILIM.

B18

31. (Twice Amended) The method of claim 25, wherein the substance is a non-protein substance.

B19

32. (Amended) The method of claim 31, wherein the non-protein substance is DNA, RNA, or a chemically synthesized compound.